Skip to content

Author

Jin-Meng Chu

We have 1 of 7 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Aug 2026

The KAT8-CDK1 K33 acetylation axis drives doxorubicin resistance by suppressing ferroptosis and apoptosis in breast cancer

KAT8-dependent CDK1 K33 acetylation is established as a key epigenetic mechanism sustaining anthracycline resistance and targeting the KAT8-CDK1 axis may provide a therapeutic strategy to overcome refractory breast cancer.

Qing-Zhi Zhao, Qi-Xian Zou, Jin-Meng Chu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.